Gene Therapy Investment At All Time High, Commercialization Challenges Noted

Investor appetite for cell and gene therapy companies has skyrocketed during the past year. However, storm clouds may gather as manufacturing and reimbursement challenges remain.

2018 saw a huge uptick in investment in gene therapy companies, but the path to efficient manufacture and commercial success for these products is still far from clear, new research from the Alliance for Regenerative Medicine suggests.

2019 has so far continued the trend, kicking off with some big investments in gene therapy companies. Biogen Inc.’s...